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Survivin is an oncogenic protein involved in cell division and acts as an anti-apoptotic factor. It is highly expressed in most cancers and
is associated with chemotherapy resistance, increased tumour recurrence, and shorter patient survival. This makes anti-survivin
therapy an attractive cancer treatment strategy. These functions are mediated by several survivin spliced variants, whose expression
may correlate with cancer progression. One of the spliced variants, survivin-DEx3, is known to inhibit apoptosis, through undefined
mechanisms. Here, we characterised these mechanisms upon TNFa mediated apoptosis, and showed that survivin-DEx3 acts as an
adaptor, allowing the formation of a complex between Bcl-2 and activated caspase-3. The Bcl-2/survivin-DEx3 complex, but not
survivin-DEx3 itself, inhibits the activity of caspase-3. Bcl-2 is therefore linked to the postmitochondrial apoptotic machinery by
survivin-DEx3. Thus, survivin-DEx3 plays a key role in the inhibition of caspase-3 activity, and in the control of the mitochondrial
checkpoint of apoptosis. This study suggests that targeting survivin-DEx3, rather than survivin alone, could be relevant for treating
human cancers.
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Survivin is an inhibitor of apoptosis, which also plays a critical role
in regulating cell cycle and mitosis (Altieri, 2004). This protein is
highly expressed in most cancers and is associated with tumour
cell resistance to apoptotic stimuli. This ability is essential during
tumourigenesis by providing cancer cells growth advantages and
conferring resistance to chemotherapy. Survivin expression is also
associated with tumour recurrence and shorter survival (Altieri,
2001; Reed, 2002).
Regulation of caspase activity is one of the mechanisms used by
cancer cells to become resistant to apoptosis (Hengartner, 2000).
This function can be achieved by the cytoplasmic inhibitor-
of-apoptosis proteins (IAPs). IAPs contain BIR (baculovirus IAP
repeat) domains, which are essential for their anti-apoptotic
properties. In several cases, BIR domains directly bind to and
inhibit caspase activities (Deveraux and Reed, 1999; Sun et al,
1999; Goyal, 2001). Caspase activities are also regulated by another
anti-apoptotic family: the Bcl-2 family (Frade and Michaelidis,
1997). In mammalian cells, several adaptor proteins, bridge
caspases to Bcl-2 or Bcl-xL, to control their activation (Ng et al,
1997; Chau et al, 2000; Zhang et al, 2003). Such adaptors link the
mitochondrial Bcl-2 family members to the postmitochondrial
apoptotic machinery, and thereby play an important role in the
regulation of apoptosis.
Survivin was originally identified by its structural homology to
the IAP family of proteins in human B-cell lymphoma (Ambrosini
et al, 1997). In human cells, there are four spliced variants of
survivin: survivin-2B; survivin-2a, survivin-3B, and survivin-DEx3.
Their expression levels correlate with cancer progression (Li,
2005). Survivin-DEx3 is generated by the removal of exon 3
(Mahotka et al, 1999; Badran et al, 2004; Caldas et al, 2005). The
open reading frame of survivin-DEx3 encodes a protein with an
interrupted BIR domain and a unique 63 amino-acid long C-
terminal tail (Mahotka et al, 1999). Overexpression of survivin-
DEx3 is observed in several human malignancies, including renal
cell carcinoma, breast cancer, gastric carcinoma, and medullo-
blastoma (Krieg et al, 2002; Mahotka et al, 2002a; Fangusaro et al,
2005; Ryan et al, 2005). In addition, expression of survivin and
survivin-DEx3 remains constant in different stages of cancer
(Krieg et al, 2002). Patients with soft-tissue sarcoma also have an
increased risk of tumour-related death when survivin-DEx3 is
overexpressed (Taubert et al, 2005). The expression level of
survivin-DEx3 is inversely correlated with apoptotic index in
gastric cancers (Meng et al, 2004).
Survivin-DEx3 inhibits apoptosis, through undefined mechan-
isms (Mahotka et al, 1999, 2002a). The protein has a unique C-
terminus, and novel anti-apoptotic features could be mediated by
this region. We previously suggested that a mitochondrial
targeting signal (MTS) and a putative BH2 domain may be
located in this region (Wang et al, 2002). Survivin-DEx3
preferentially localises in the nucleus during late G1 to G2 phases
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sof the cell cycle (Fortugno et al, 2002). A nuclear localisation
signal (NLS) is embedded in its unique C terminus (Mahotka
et al, 2002b). Survivin-DEx3 is also distributed in the cytosol,
with a fraction located at the mitochondria in HeLa and Daoy
cells (Rodriguez et al, 2002; Mahotka et al, 2002b; Caldas et al,
2005; You et al, 2006). Survivin and survivin-DEx3 form
heterodimers, thereby regulating the balance between proliferation
and cell death (Caldas et al, 2005). Other binding partners
may additionally contribute to the anti-apoptotic function of
survivin-DEx3.
Previously, we showed that a viral protein vIAP (viral inhibitor-
of-apoptosis protein), which is encoded by ORF K7 of human
Kaposi’s sarcoma-associated herpesvirus (KSHV), is an adaptor
between Bcl-2 and activated caspase-3, thereby, enabling Bcl-2 to
inhibit caspase-3 activity (Wang et al, 2002). We found that vIAP is
structurally and functionally related to survivin-DEx3: both
proteins contain a disrupted BIR domain, an MTS, and a putative
BH2 domain (Wang et al, 2002). However, it is not yet clear,
whether survivin-DEx3 also achieves its anti-apoptotic function in
a similar way to that of vIAP. We hypothesised that survivin-DEx3
may achieve its anti-apoptotic function by bridging mitochondrial
proteins, such as Bcl-2, to caspases.
Here, we showed that upon TNFa treatment, survivin-DEx3
localises at the mitochondria, where it binds to Bcl-2 and to
activated caspase-3, acting as an adaptor, which allows Bcl-2 to
inhibit the activity of caspase-3. Thus, this study suggests that
survivin-DEx3 is a central regulator at the mitochondrial
checkpoint during TNFa-induced apoptosis.
MATERIALS AND METHODS
Plasmids
pCR3.1-survivin and pCR3.1-survivin-DEx3 expressing haemag-
glutinin-tagged forms were described previously (Wang et al,
2002). pCR3.1-survivin-DEx3(DBIR) (deleted aa 38–43) and
pCR3.1-survivin-DEx3(DBH2) (deleted aa 101–107) were created
using the QuickChange mutagenesis kit (Stratagene, Amsterdam,
The Netherlands) to introduce deletion mutations in pCR3.1-
survivin-DEx3. pGST-survivin-DEx3(118), pGST-survivin-DEx3(100),
pGST-survivin-DEx3(70), and pGST-survivin-DEx3(CT) were
created by PCR amplification from pCR3.1-survivin-DEx3, and
then cloned in pGEX6P1 vector (Amersham Pharmacia Biotech,
Bucks, UK).
RNA interference
Targets for RNA interference were selected using the Dharmacon
sequence selection tool (www.dharmacon.com). First, we at-
tempted to develop a survivin-DEx3-specific siRNA. Since survivin
contains all the sequences that survivin-DEx3 has, we designed
siRNA using the only specific sequences of survivin-DEx3 at the
junction of exons 2 and 4, but we did not obtain any knock-down
effect. In consequence, a global approach to knock-down survivin-
DEx3 was used. DNA oligos containing the target sequence, a
TTCG hairpin, the antisense of the target, a five T termination
sequence, and a CTAG (XbaI site) were synthesised by (MWG
Biotech, London, UK), annealed and inserted into the pGEM-U6M
plasmid by digestion with XbaI and SmaI (Promega, Southampton,
UK) and ligated with T4 DNA ligase (NEB, Herts, UK). pGEM-U6M
was created from pGEM-U6L and altering the þ1 base pair of the
U6 promoter from G to C using the Stratagene quickchange site
directed mutagenesis kit. Lentiviral RNA interference plasmids
were then generated by subcloning the U6 promoter-hairpin
construct from pGEM-U6M into pCSGW by digestion with EcoRI.
The short hairpin targeting all three survivin isoforms is
ggaccaccgcatctctacattc.
Glutathione S-transferase (GST) pull-down,
immunoprecipitation, Western blot, and
immunofluorescence microscopy
The expression of recombinant glutathione S-transferase (GST)
fusion proteins, GST pull-down assays, in vivo co-immunopreci-
pitations, and Western blots were described previously (Wang
et al, 2002). The following primary antibodies were used: anti-
survivin (6E4 mAb, Cell Signaling, Danvers, USA), anti-HA
(BabCo, Cambridge, MA, USA), anti-cytochrome c (Upstate,
Chandlers Ford, UK), anti-Bcl-2 (BD Pharmingen, Oxford, UK),
anti-caspase-3 (BD Pharmingen). Transfections were performed
using fuGENE6 transfection reagent (Roche, Welwyn Garden City,
UK). For immunofluorescent assay (IFA), HeLa cells were fixed
and permeabilised using formalin 3.7% and PBS-T-0.1% Triton X-
100, as previously described (Wang et al, 2002). Images were taken
using a confocal microscope (Leica TSC Systems, Bucks, UK).
Subcellular fractionations
A method described previously (Wang et al, 2002) was used to
divide cells into intact nucleus, intact mitochondria, and cytosol
fractions
RNA extraction and RT–PCR
RNA extraction and RT–PCR were performed, as previously
described (Wang et al, 2002). The sense primer for specific
amplification of survivin-DEx3 cDNA is as follows: 50-GACG
ACCCCATGCAAAGGAAAC-30, and the antisense primer is the
same as that used for survivin-DEx3/survivin cloning.
Comparative protein modelling and bioinformatics tools
The MODELLER program (http://salilab.org/modeller/model-
ler.html) was applied in the comparative modelling work (Sanchez
and Sali, 2000). Protein templates used in comparative modelling
were downloaded from the PDB database (http://www.rcsb.org/
pdb/index.html). The RasMol software (www.umass.edu) and the
Swiss-PdbViewer program (v3.7) (www.expasy.org/spdbv) were
used to view and analyse the resulting models. To further
characterise the intracellular localisation of different proteins,
we used the TMprep program (www.ch.embnet.org/software/
TMPRED_form.html), which makes a prediction of membrane-
spanning regions and their orientation based on the statistical
analysis of the TMbase database (www.ch.embnet.org/software/
tmbase/TMBASE_doc.html). Another independent algorithm,
the TopPrep program (bioweb.pasteur.fr/seqanal/interfaces/top-
pred.html), is also used to confirm the reliability of the TMprep
program.
Induction of apoptosis, apoptotic assays, and flow
cytometry analyses
For TNFa-induced apoptosis, transfected HeLa cells were cultured
in the presence of 10ngml
 1 of TNFa (Sigma, Gillingham, UK)
plus 1mgml
 1 of cycloheximide (Sigma) for the indicated time
period. For Bax-induced apoptosis, 4 10
5 of cells were trans-
fected with Bax-expression plasmids and incubated at 371C for 48h
or 24h. To measure mitochondrial transmembrane potential
(DCm), 5 10
5 of transfected cells were incubated with 500mM
of CMXRosamine (Molecular Probes, Paisley, UK) at 371C for
30min. To evaluate cell viability, cells were resuspended in
propidium iodide (PI) solution (2mgml
 1 PI in PBS with 1%
BSA and 0.01% azide, BD Pharmingen, UK) at 201C for 20min.
Treated cells were washed in PBS, then analysed for fluorescence
using FACSCaliburt flow cytometry with the CellQuest software
(Becton Dickinson, Franklin Lakes, NJ, USA). A total of 20000 cells
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swere counted in each experiment, and the numbers reported
represent the average and standard deviation (s.d.) of at least three
independent experiments. For the caspase-3 activity assays, we
used the ApoAlert caspase-3 fluorescent assay kit (Clontech, Saint-
Germain-en-Laye, France).
RESULTS
Expression of survivin-DEx3 in human cancer and normal
cell lines
The domain organisation of survivin, survivin-2B, survivin-DEx3,
and vIAP is represented in Figure 1A. We investigated the
transcriptional expression of survivin and survivin-DEx3 in several
human cancer and normal cell lines. The mRNA of survivin-DEx3
is detected by semiquantitative RT–PCR in cell lines derived from
human cancers, like for Kaposi sarcoma (lanes 2, 3), cervival
carcinoma (lane 4), fibrosarcoma (lane 5), non-small lung
carcinoma (lane 7), osteosarcoma (lanes 8–9), leukaemia (lane
13), and also from cell lines established from normal tissues, like
embryonic kidney cells (lane 1), pulmonary epithelial cells (lane 6),
endothelial cells from umbilical vein (lanes 10, 11). All the cell lines
tested were positive for survivin-DEx3 (Figure 1B). Expression of
both survivin and survivin-DEx3 transcripts has also been detected
in human primary cells (Figure 1C). Survivin-DEx3, like survivin
(Adida et al, 1998), is detectable in fetal tissues, suggesting that this
protein may be another oncofetal protein deregulated in cancers.
Localisation of survivin-DEx3 and vIAP
We next analysed the sequence of survivin, survivin-DEx3, and
vIAP, using computational protein modelling tools. Two different
computational analyses suggested a putative localisation to the
membrane of survivin-DEx3, with inside-out orientation of the
C-terminus domain (Figure 1D).
We next characterised the localisation of survivin-DEx3 and
vIAP using IFA in survivin-DEx3- or vIAP-expressing HeLa cells,
stained with a mitochondria-specific dye (Figure 1E). Consistent
with previous reports (Caldas et al, 2005; You et al, 2006),
survivin-DEx3 and vIAP are localised in the nucleus, the cytosol,
and particularly in the mitochondria (Figure 1E). Using subcellular
fractionation assays, we showed that both proteins can be found in
the mitochondrial fraction in HeLa cells. The mitochondrial
distribution pattern of survivin-DEx3 and vIAP was similar to
that of Bcl-2, but distinct from that of survivin (Figure 1F), which
is known to reside in the cytoplasm and to translocate into the
nucleus during mitosis (Fortugno et al, 2002).
Survivin-DEx3 protects cells from apoptosis
We tested if survivin-DEx3 shares with vIAP its ability to protect
cells from apoptosis, upon different apoptotic treatments. We
investigated the mitochondrial function of survivin-DEx3, and
showed that the expression of survivin-DEx3 prevents cytochrome
c release in 293 cells upon Bax-induced apoptosis (Figure 3C) and
protects HeLa cells from TNFa-induced apoptosis (Figure 1G). The
ability of survivin-DEx3 to protect cells from apoptosis was
comparable to that of KSHV vIAP, survivin, and Bcl-2. It was
reported that the diverse functions of survivin may be explained
partly by its ability to heterodimerise with its splicing variants in
tumour cells (Caldas et al, 2005). Survivin and survivin-DEx3
interact at the mitochondria, where they may protect cells from
mitochondrial-dependent apoptosis (Caldas et al, 2005). Using a
GST pull-down, we further showed that both vIAP and survivin-
DEx3 could heterodimerise with survivin, via the BIR domain
(Figure 1H).
Survivin-DEx3 associates with both Bcl-2 and activated
caspase-3
Next, we investigated the mechanisms by which survivin-DEx3
inhibits TNFa-mediated apoptosis. Certain mammalian IAPs and
the KSHV vIAP are able to bind directly to caspases, via their BIR
domains (Deveraux and Reed, 1999; Goyal, 2001; Wang et al,
2002). We therefore investigated whether the disrupted BIR
domain of survivin-DEx3 could still bind to the active form of
caspase-3. To gain further insights into the interaction between
activated caspase-3 and survivin-DEx3, we computationally
modelled the putative survivin-DEx3–caspase-3 complex. Accord-
ing to the published structure of the XIAP BIR2-caspase-3 complex
(PDB ID: 1I3O (Riedl et al, 2001), Figure 2A, lower panel), the
topological contact between survivin-DEx3 and active caspase-3 is
predicted to be through the globular BIR domain of survivin-DEx3
with the edge, but not with the catalytic pocket of the enzyme
caspase-3 (Figure 2A, upper panel). In contrast, it is reported that
XIAP can further bind to the substrate-binding cleft of active
caspase-3, via its N-terminal linker, hence, providing a steric
blockade mechanism for substrate binding (Figure 2A, lower
panel). This computational model implied that although survivin-
DEx3 could bind to active caspase-3, this interaction may not be
sufficient for survivin-DEx3 to inhibit the activity of this enzyme.
Other cofactors may be required for the anti-apoptotic function of
survivin-DEx3.
We tested if survivin-DEx3 can interact directly with activated
caspase-3. Four different deletion mutants of survivin-DEx3 were
designed and cloned in fusion with recombinant GST to map the
different domains within survivin-DEx3 potentially involved in the
interaction with caspase-3 (Figure 2B, upper panel), and a GST
pull-down assay was performed. We showed that recombinant
active caspase-3 is pulled down by survivin-DEx3 and that only the
interrupted BIR domain is necessary and sufficient for this
interaction (Figure 2B, lanes 1 and 4). These interactions were
specific, as GST only, or the C-terminus of survivin-DEx3, which
does not contain BIR domain did not pull down active caspase-3
(Figure 2B, lanes GST and 2).
We have previously shown that the KSHV vIAP suppresses
caspase-3 activity, only when it also binds to Bcl-2 (Wang et al,
2002). It is possible that survivin-DEx3 also inhibits indirectly
caspase-3 activity, by also binding to Bcl-2. We therefore tested
survivin-DEx3 and Bcl-2 interaction by in vivo co-immunopreci-
pitation (IP) in HeLa cell extracts expressing vIAP, survivin-DEx3,
and survivin-DEx3(DBH2) with an anti-Bcl-2 mAb. We showed
that survivin-DEx3 and vIAP (used here as a positive control), but
not the BH2 domain-deleted survivin-DEx3 mutant, were im-
munoprecipitated with endogenous Bcl-2 (Figure 2C). This
experiment showed that survivin-DEx3 binds to Bcl-2 via its BH2
domain.
To test the interaction between Bcl-2 and activated caspase-3, an
in vivo Bcl-2 IP was performed in a TNFa-treated HeLa cell lysate
expressing endogenous survivin-DEx3. The active form of caspase-
3 was immunoprecipitated with Bcl2, validating the existence of a
tripartite complex between survivin-DEx3, Bcl-2, and active
caspase-3 (Figure 2D).
The ability of survivin-DEx3 to mediate the interaction between
caspase-3 and Bcl-2 was tested by knocking down endogenous
survivin-DEx3. Short hairpin RNAs expressed by a lentiviral
vector were used to eliminate the expression of all endogenous
survivin isoforms, and an in vivo Bcl2 IP was performed on
survivin-DEx3 positive- and negative-HeLa cell lysates. Activated
caspase-3 could be immunoprecipitated in complex with Bcl-2,
only when survivin-DEx3 is present (Figure 2E). The absence of
caspase-3 on Bcl-2 IP when all isoforms of survivin are knocked
down is likely to be due to the absence of survivin-DEx3, rather
than survivin, as survivin does not interact with Bcl-2 (Supple-
mentary Figure B).
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sSurvivin-DEx3 associates with Bcl-2 to inhibit the function
of activated caspase-3
The functional significance of the association between survivin-
DEx3, Bcl-2, and active caspase-3 was further addressed by testing
the ability of survivin-DEx3 and several mutants to inhibit
endogenous caspase-3 activity upon TNFa-induced apoptosis,
using a caspase fluorescent substrate assay. We found that
survivin-DEx3, like vIAP (Wang et al, 2002), inhibits caspase-3
activity. Such inhibition required the presence of a functional BH2
domain (necessary for binding to Bcl-2) and also a functional BIR
domain (necessary for binding to caspase-3; Figure 3A). Using
recombinant caspase-3 also showed that both BH2 and BIR
domains are required (Supplementary Figure A). Overall, these
data indicate that survivin-DEx3 protects cells from TNFa-induced
apoptosis, by acting through a caspase-3-dependent pathway.
Finally, we investigated whether the ability of survivin-DEx3 to
associate to Bcl-2 and caspase-3 is essential for its anti-apoptotic
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sfunction. The BH2 and BIR domains of survivin-DEx3 were
deleted, and we monitored for each mutant their aptitude to
protect cells by measuring the loss of mitochondrial membrane
potential (Dcm), using a dye specific for intact mitochondrial
membranes (Figure 3B). Survivin-DEx3 protects HeLa cells from
TNFa-induced apoptosis as much as vIAP, used here as a positive
Figure 1 Structure–function relationships of survivin-DEx3 and KSHV vIAP protein (vIAP). (A) Domain organisation of survivin, survivin-2B, survivin-
DEx3, and vIAP. The discrete domains (D), involved in dimerisation, BIR and BH2-like domains, the zinc-finger motif, the microtubule binding, the nuclear
localisation signal (NLS), mitochondrial targeting signal (MTS) and N-glycosylation (N-Gly) signal are shown. (B) Reverse transcription-PCR (RT–PCR)
detection of survivin-DEx3 transcripts in different cell lines. Lane 1: 293T; lane 2: KS Y-1; lane 3: KS-IMM; lane 4: HeLa; lane 5: HT1080; lane 6: A549; lane 7:
H1299; lane 8: Saos2; lane 9: U2OS; lane 10: 1E7; lane 11: ECV304; lane 12: HE-1; lane 13: THP1 cells. (þ) cDNA of survivin-DEx3 was used as a positive
control. ( ) water-only negative control. (C) RT–PCR detection of survivin-DEx3 transcripts in human primary cells. Lane 1: HUVEC; lane 2: MSC; lane 3:
DMVEC; lane 4: adult bone marrow mononuclear cells. (D) Schematic representation of the transmembrane potential orientations of survivin-DEx3 and
vIAP (TopPrep program). (E) Immunofluorescent assays on cells expressing HA-tagged survivin-DEx3 or vIAP. Green: SurDEx3 or vIAP, blue: DNA stained
with Hoechst, red: mitochondria stained with MitoTracker dye. The overlay is presented on the right panel. (F) Subcellular fractionation of 293T cells
transfected with survivin-DEx3, survivin, and HA-vIAP. Transfected cells were separated into cytoplasmic (c) and mitochondrial (m) fractions and analysed by
Western blot with anti-survivin-DEx3, -HA, and -Bcl-2 antibodies. (G) Survivin-DEx3 rescues cells from TNFa-induced apoptosis. 48h after transfection,
HeLa cells were treated with TNFa (10ngml
 1) plus cycloheximide (1mgml
 1) for 2h, pooled, washed and stained with propidium iodide (PI) to assess cell
viability and counted by flow cytometry. Results represent the mean7standard deviation of four independent experiments. (H) Both survivin-DEx3 and
vIAP bind to survivin in vitro. The indicated GST-fusion proteins on glutathione beads were incubated with HA-tagged survivin-expressing 293T lysates, and
specifically bound proteins were analysed by Western blot with an anti-HA.
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Figure 2 Survivin-DEx3 functions as an adaptor. (A) A predicted model for survivin-DEx3 in complex with active caspase-3. Caspase-3 catalytic domain
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with an arrow. This model is based on the existing interaction between active caspase-3 and the XIAP BIR2 domain (lower panel). (B) Survivin-DEx3
interacts directly through its BIR domain with active caspase-3. Upper, schematic representation of the domain organisation of the recombinant proteins.
Green lines indicate caspase-3-binding proteins, while red does not. Lower, bound caspase-3 is analysed by Western blot with an anti-active caspase-3
polyclonal antibody. A Coomassie blue-stained gel shows the expression level of the different mutants. (C) Survivin-DEx3 binds to Bcl-2 in vivo, through its
BH2 domain. Immunoprecipitations were performed in HeLa transfected with indicated plasmids. (D) Bcl-2 precipitates active caspase-3 in the presence of
survivin-DEx3. Survivin-DEx3-expressing HeLa cells were treated with TNFa (10ngml
 1) plus cycloheximide (1mgml
 1) for 2h. Immunoprecipitations were
performed as previously, and were analysed with anti-active caspase-3 antibody. (E) Survivin-DEx3 is an essential bridge between Bcl-2 and active caspase-3.
HeLa cells were pre-infected with either empty lentivirus (V) or lentivirus stably expressing RNAi against all isoforms of survivin (KO). Apoptosis and
immunoprecipitation were performed as described previously.
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scontrol (Figure 3B). The deletion of the BH2 or of the BIR domains
resulted in a significant reduction of the anti-apoptotic activity of
survivin-DEx3 (Figure 3B).
We also monitored the translocation of cytochrome c from
mitochondria into the cytosol, as a marker for mitochondrial
integrity, upon Bax-induced apoptosis in 293T cells. Survivin-
DEx3 prevented cytochrome c translocation, while the two mutants
did not (Figure 3C). The different protective effects of survivin-
DEx3 mutants cannot be attributed to variations in protein
expression level, since all mutants were expressed similarly
(Figure 3, Western blot), and all survivin-DEx3 remained localised
at the mitochondria. Overall, these data suggest that binding to
active caspase-3 alone or Bcl-2 alone is not sufficient for survivin-
DEx3 to inhibit the enzymatic activity of caspase-3. To achieve a
complete anti-apoptotic function, survivin-DEx3 requires an
association with both partners (Figure 3).
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Figure 3 Functional analysis. (A) Requirement of both survivin-DEx3 BH2 and BIR domains for caspase-3-inhibition. At 48h after transfection of the
indicated plasmids, and after 2h of TNFa/CHX treatment, fluorescent substrate (Sub) and cellular extracts expressing the different constructs were mixed
together and reactions were incubated for 1h at 371C, before monitoring fluorescence on a fluoremeter. Results present caspase-3 activity in per cent, each
sample standardised to the noninduced cellular extracts, as requested by the manufacturer. (B) Both BH2 and BIR domains of survivin-DEx3 are essential for
its anti-apoptotic function. At 48h after transfection, in HeLa cells transfected with the indicated expression constructs and exposed to TNFa/cycloheximide
during 2h, MitoTracker was used to measure the loss of mitochondrial membrane potential (DCm). Inhibition percentage was calculated as follows: (%
apoptosis in vector-transfected cells) (% apoptosis in the indicated DNA-transfected cells)/(% apoptosis in vector-transfected cells), where % apoptosis is
the percentage of apoptotic cells relative to total cells. (C) Survivin-DEx3 can inhibit Bax-induced cytochrome c translocation. Subcellular fractionation assays
were performed with 293T cells expressing the different constructs. Cytosolic fraction (C) and mitochondrial fractions (Mito) were blotted with an anti-
cytochrome c antibody.
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We have shown that survivin-DEx3 shares a number of similarities
with vIAP (Figure 1; Wang et al, 2002), such as their localisation to
the mitochondrial compartment, their ability to heterodimerise
with survivin, and their anti-apoptotic activity upon TNFa
treatment. One of the anti-apoptotic mechanisms of survivin-
DEx3 is mediated by its association with both Bcl-2 and active
caspase-3, in order to inhibit the activity of the bound enzyme
(Figures 2 and 3). These data confirm our hypothesis that survivin-
DEx3 is an anti-apoptotic factor, functioning like vIAP (Wang
et al, 2002).
It is known that survivin-DEx3 is overexpressed in a number of
tumours, and may contribute to tumourigenesis by protec-
ting malignant cells from apoptosis by undefined mechanisms
(Mahotka et al, 1999, 2002a, 2002b). Our data provide further
insights into these mechanisms. Survivin-DEx3, like survivin,
protects cells from methotrexate, lymphotoxin-b receptor, and
CD95-induced apoptosis (You et al, 2006). Here, we showed that
survivin-DEx3 also protects cell from TNFa-induced apoptosis,
defining survivin-DEx3 as a key factor of the mitochondrial
checkpoint of apoptosis.
In mammals, several adaptor proteins bridge caspases to Bcl-2
or Bcl-xL to prevent their activation. For example, Bap31
contributes to the regulation of procaspase-8, and this activity is
dependent on the presence of Bcl-2 or Bcl-xL within the same
complex (Ambrosini et al, 1997). A novel BH3-only protein, Spike,
inhibits the formation of a complex between Bap31 and Bcl-xL,
thereby favouring apoptosis (Mund et al, 2003). We previously
showed that vIAP functions as an adaptor linking Bcl-2 to
activated caspase-3, and thereby controlling its activity (Wang
et al, 2002). Here, we showed that one of the anti-apoptotic
mechanisms of survivin-DEx3 is also to act as an adaptor, linking
Bcl-2 to active caspase-3, through its BH2 and BIR domains,
respectively. This enables Bcl-2 to inhibit the activity of caspase-3
and to protect cells from apoptosis. Using a knock-down approach,
we have demonstrated that survivin-DEx3 is essential to link Bcl-2
to caspase-3. Indeed, without any survivin-DEx3 expression
detectable, we significantly reduced the quantity of caspase-3
interacting with Bcl-2 (Figure 2E). Survivin-DEx3 provides a link
between two major apoptotic pathways. Our data were obtained in
the context of TNFa-induced apoptosis, which is one of the main
pathways involved in the control of cell survival–apoptosis
balance.
We also studied the role of survivin-DEx3 upon Bax-induced
apoptosis, which is part of the TNFa-induced responses. We showed
that survivin-DEx3 is able to maintain the mitochondrial transmem-
brane potential and to prevent the translocation of cytochrome c
from mitochondria (Figure 3C). This concurs with recent data
showing that overexpression of survivin-DEx3 prevents LTbR-
induced release of cytochrome c and Smac/DIABLO. LTbRi sa
member of another TNF superfamily group, which is specifically
involved in developmental programmes (You et al, 2006).
Some members of the IAP family are E3 ubiquitin ligases (Vaux
and Silke, 2005), involved in substrate ubiquitination and
degradation by the 26S proteasome. For example, XIAP and livin
protect cells from TRAIL-induced apoptosis by targeting pro-
apoptotic molecules, such as Smac/DIABLO, for proteasomal
degradation (MacFarlane et al, 2002; Ma et al, 2006). It remains to
be investigated whether survivin-DEx3 holds ubiquitin-ligase
activity, or interacts with an E3 ligase to protect cells from
mitochondrial damage by targeting pro-apoptotic molecules for
proteasomal degradation. In TNFa-induced responses, caspase-
independent signalling pathways are also involved. We showed
here that survivin-DEx3, upon TNFa-induced cell death, prevents
the activation of caspase-3. As some IAPs regulate apoptosis by
interacting with various components of the MAPK family (Zhang
et al, 2003; You et al, 2006), survivin-DEx3 may also be able to play
a role via caspase-independent pathways.
We have also shown that survivin-DEx3 is able to hetero-
dimerise with survivin. This suggests that the splice variants of
survivin contribute to regulate the balance between proliferation
and cell death. As survivin links cell proliferation, survival, and
stress responses, studies targeting survivin are being exploited,
using diverse approaches from immunotherapy to small molecule
antagonists (Altieri, 2006). Targeting survivin-DEx3, rather than
survivin alone, may selectively and effectively destroy tumour cells,
by suppressing their ability to resist apoptosis. Overall, these
findings suggest that survivin-DEx3 is a potential target for future
anti-cancer therapies.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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